Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Sept 2012

Bejar Rafael, Stevenson Kristen E, Caughey Bennett A, Abdel-Wahab Omar, Steensma David P, Galili Naomi, Raza Azra, Kantarjian Hagop, Levine Ross L, Neuberg Donna, Garcia-Manero Guillermo, Ebert Benjamin L

Abstract excerpt

PURPOSE: A subset of patients with myelodysplastic syndromes (MDS) who are predicted to have lower-risk disease as defined by the International Prognostic Scoring System (IPSS) demonstrate more aggressive disease and shorter overall survival than expected. The identification of patients with greater-than-predicted prognostic risk could influence the selection of therapy and improve the care of patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer of Zeste Homolog 2 Protein
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Multivariate Analysis

Share to Myelodysplastic Syndromes

Share to Polycomb Repressive Complex 2

Share to Predictive Value of Tests

Share to Reproducibility of Results

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 22869879
DOI: 10.1200/JCO.2011.40.7379
PMCID: PMC3438234

Genes

ASXL1
RUNX1
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.PMID 22869879Read ↗

Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.Semantic proximity Read ↗

Prognostic models in myelodysplastic syndromes.Semantic proximity Read ↗

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.Semantic proximity Read ↗

The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.Semantic proximity Read ↗

When to use which molecular prognostic scoring system in the management of patients with MDS?Semantic proximity Read ↗

Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.Semantic proximity Read ↗

Critical Role of Molecular-Based Stratification in Low-Risk Myelodysplastic Syndrome with Direct Progression to Acute Myeloid Leukemia: A Case Report.Semantic proximity Read ↗

Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.Semantic proximity Read ↗

[Molecular international prognostic scoring system for myelodysplastic syndromes].Semantic proximity Read ↗

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.Semantic proximity Read ↗

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.